Prevalence and prognostic value of c-erbB2 expression in non-small cell lung cancer (NSCLC)

Neoplasma

Volumn 50, Issue 4, 2003, Pages 257-261

  Turken, O ^a   Kunter, E ^a   Cermik, H ^b   Isitmangil, T ^a   Kandemir, G ^a   Yaylaci, M ^a   Ozturk, A ^a  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

C erbB2; Cancer; Lung; Non small

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOPROTEIN; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; PREVALENCE; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; STAINING;

EID: 0141426787     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. AGUS DB, BUNN PA JR, FRANKLIN W, GARCIA M, OZOLS RF. HER2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer and ovarian cancer. Semin Oncol 2000; 27: 53-63.
2. BRABENDER J, DANENBERG K, METZGER R, SCHNEIDER PM, PARK J, SALONGA D, HOLSCHER AH, DANENBERG PV. Epidermal growth factor receptor and HER2/neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001; 7: 1850-1855.
3. Cox G, VYBERG M, MELGAARD B, ASKAA J, OSTER A, O'BYRNE KJ. Herceptest: HER2 expression and gene amplification in non-small cell lung cancer. Int J Cancer 2001; 92: 480-483.
4. DEPOWSKI PL, BRIEN TP, SHEEHAN CE. Prognostic significance of p34cdc2 cyclin-dependent kinase and MIBI overexpression and HER2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer. Am J Clin Pathol 1999; 112: 459-469.
5. GIATROMANOLAKI A, KOUKUORAKIS MI, O'BYRNE K. Non-small cell lung cancer: c-erbB2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Res 1996; 16: 3819-3825.
6. GINSBERG RJ, VOKES EE, ROSENWEIG K. Non-small cell lung cancer. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer, Principles and Practice of Oncology. Philadelphia: Lippincott-Williams and Wilkins Com, 2001: 925-927.
7. GRAZIANO SL, TATUM A, HERNDON JE, BOX J, MEMOLI V, GREEN MR, KERN JA. Use of neuroendocrine markers, p53 and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a cancer and leukemia Group B study. Lung Cancer 2001; 33: 115-123.
8. GROTH G, HIRSH V, BUTTS V. A randomised phase II study of gemcitabine/cisplatin alone and with herceptin in patients with HER2-positive non-small cell lung cancer (NSCLC). Eur J Cancer 2001; 37: 50.
9. HIRASHIMA N, TAKAHASHI W, YOSIHI S, YAMANE T, OOI A. Protein overexpression and gene amplification of c-erbB2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol 2001; 14: 556-562.
10. HSIEH CC, CHOW KC, FAHN HJ. Prognostic significance of HER2/neu overexpression in stage I adenocarcinoma of lung. Ann Thorac Surg 1998; 66: 1159-1164.
11. KLAPPER LN, GLATHE S, VAISMAN N, HYNES NE, ANDREWS GC, SELA M, YARDEN Y. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 1999; 9: 4995-5000.
12. KLIJANIENKO J, COUTURIER J, GALUT M. Detection and quantitation by fluorescence in situ hybridization (FISH) and image analysis of HER2/neu gene amplification in breast cancer fine-needle samples. Cancer 1999; 87: 312-318.
13. KRISTIANSEN G, YU Y, PETERSEN S, KAUFMANN O, SCHLÜNS K, DIETEL M, PETERSEN I. Overexpression of c-erbB-2 protein correlates with disease-stage and chromosomal gain at the c-erbB-2 locus in non-small cell lung cancer. Eur J Cancer 2001; 37: 1089-1095.
14. LOPEZ-GUERRERO JA, BOLUFER-GILABERT P, VERA-SEMPERE FJ, MARUGAN DE LA CONCHA I, BARRAGON GONZALES E. c-erbB- 2 expression and its relationship with ploidy, p53 abnormalities and epidermal growth factor receptor content in human non-small cell lung cancer. Clin Chim Acta 1999; 285: 105-120.
15. MAURER-GEBHARD M, SCHMIDT M, AZEMAR M, STOCKLIN E, WELS W, GRONER B. A novel animal model for the evaluation of efficacy of drugs directed against the erbB2 receptor on metastasis formation. Hybridoma 1999; 18: 69-75.
16. MITCHELL MS, PRESS MF. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. Semin Oncol 1999; 26: 108-116.
17. MOUNTAIN CF. Revision in the international system for staging lung cancer. Chest 1997; 111: 1710-1717.
18. AL MOUSTAFA AE, ALAOUI-JAMALI M, PATERSON J, O'CONNOR-MCCOURT M. Expression of P185erbB-2, P16erbB- 4, and heregulin alpha in human normal bronchial epithelial and lung cancer cell lines. Anticancer Res 1999; 19: 481-486.
19. PARKIN DM. Trends in lung cancer worldwide. Chest 1989; 96: 55.
20. PASTORINO U, ANDREOLA S, TAGLIABUE E. Immunocytochemical markers in stage-I lung cancer: relevance to prognosis. J Clin Oncol 1997; 15: 2858-2865.
21. PFEIFFER P, CLAUSEN PP, ANDERSEN K, ROSE C. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER2 in patients with systemically untreated non-small cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 1996; 74: 8691.
22. REINMUTH N, BRANDT B, KUNZE WP, JUNKER K, THOMAS M, ACHATZY R, SCHELD HH, SEMIK M. Ploidy, expression of erbB1, erbB2, p53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur Respir J 2000; 16: 991-996.
23. Ross JS, FLETCHER JA. HER2/neu (c-erbB2) gene and protein in breast cancer. Am J Clin Pathol 1999; 112: 553-567.
24. SCHARML P, KONONEN J, BUBENDORF L, MOCH H, BISSIG H, NOCITO A, MIHATSCH MJ, KALLIONIEMI OP, SAUTER G. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999; 5: 1966-1975.
25. SCHEURLE D, JAHANZEB M, ARONSOHN RS, WATSEK L, NARAYAN R. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Herceptest. Anticancer Res 2000; 20: 2091-2096.
26. SCHNEIDER PM, PRAEUER HW, STOELTZING O, BOEHM J, MANNING J, METZGER R, FINK U, WEGERER S, HOELSCHER AH, ROTH JA. Multiple molecular marker testing (p53, Ki-ras, c-erbB2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer 2000; 83:473-479.
27. SHI D, HE G, CAO S. Overexpression of the c-erbB-2/neuencoded p185 protein in primary lung cancer. Mol Carcinog 1992; 5: 213-218.
28. TATEISHI M, ISHIDA T, MITSUDOMI T, KANEKO S, SUGIMACHI K. Prognostic value of c-erbB2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 1991; 27: 1372-1375.
29. THOR AD, BERRY DA, BUDMAN DR. c-erbB2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Inst 1989; 90: 1346.
30. TRAVIS WD (ed). WHO histological typing of lung and pleural tumours. Genova: WHO, 1999.
31. TSAI CM, CHANG KT, LI L, PERNG RP, YANG LY. Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER2/neu gene expression and epidermal growth factor receptor level in non-small cell lung cancer cells. Jpn J Cancer Res 2000; 91: 213-222.
32. VOLM M, EFFERTH T, MATTERN J. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res 1992; 12: 11-20.
33. VOS CB, TER HAAR NT, ROSENBERG C. Genetic alterations on choromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histological type. Br J Cancer 1999; 81: 1410-1418.
34. WINER EP, MORROW M, OSBORNE CK, HARRIS JR. Malignant tumors of the breast. Prognostic and predictive factors. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer, Principles and Practice of Oncology. Philadelphia: Lippincott-Williams and Wilkins Com, 2001: 925-927.
35. YOSHIMURA C, NOMURA S, YAMAOKA M, OHTANI T, MATSUZAKIS T, YAMAGUCHI K, FUKUHARAL S. Analysis of serum erbB-2 protein and HLA-DRB1 in Japanese patients with lung cancer. Cancer Lett 2000; 28: 87-95.